Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Cash & Equivalents (2023 - 2025)

Rallybio (RLYB) has disclosed Cash & Equivalents for 3 consecutive years, with $31.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 125.66% to $31.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.4 million through Dec 2025, up 125.66% year-over-year, with the annual reading at $31.4 million for FY2025, 125.66% up from the prior year.
  • Cash & Equivalents hit $31.4 million in Q4 2025 for Rallybio, down from $32.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $39.5 million in Q1 2023 to a low of $9.4 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $23.2 million across 3 years, with a median of $21.9 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 51.16% in 2024 and later skyrocketed 125.66% in 2025.
  • Year by year, Cash & Equivalents stood at $24.5 million in 2023, then plummeted by 43.24% to $13.9 million in 2024, then surged by 125.66% to $31.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for RLYB at $31.4 million in Q4 2025, $32.1 million in Q3 2025, and $9.4 million in Q2 2025.